Cargando…

[(18)F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[(18)F]FDG PET/CT

PURPOSE: This study aimed to assess the diagnostic performance of [(18)F]FAPI-42 PET/CT and compare it with that of 2-[(18)F]FDG PET/CT in patients with differentiated thyroid cancer (DTC) with biochemical elevations in Tg or anti-Tg antibodies. METHODS: A total of 42 patients with DTC with biochemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Xingyu, Huang, Xiaoxue, Jiang, Zewen, Li, Meng, Jia, Lulu, Lv, Zhongyuan, Fu, Wei, Mao, Jingsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931817/
https://www.ncbi.nlm.nih.gov/pubmed/36495325
http://dx.doi.org/10.1007/s00259-022-06067-2
_version_ 1784889316592320512
author Mu, Xingyu
Huang, Xiaoxue
Jiang, Zewen
Li, Meng
Jia, Lulu
Lv, Zhongyuan
Fu, Wei
Mao, Jingsong
author_facet Mu, Xingyu
Huang, Xiaoxue
Jiang, Zewen
Li, Meng
Jia, Lulu
Lv, Zhongyuan
Fu, Wei
Mao, Jingsong
author_sort Mu, Xingyu
collection PubMed
description PURPOSE: This study aimed to assess the diagnostic performance of [(18)F]FAPI-42 PET/CT and compare it with that of 2-[(18)F]FDG PET/CT in patients with differentiated thyroid cancer (DTC) with biochemical elevations in Tg or anti-Tg antibodies. METHODS: A total of 42 patients with DTC with biochemical elevations in Tg or anti-Tg antibodies underwent [(18)F]FAPI-42 PET/CT as part of this study; of which, 11 additionally underwent 2-[(18)F]FDG PET/CT within 7 days. Images were semi-quantitatively and visually interpreted, and the quantity, location, and uptake values of lesions were noted. The diagnostic capacity of [(18)F]FAPI-42 PET/CT and biomarkers affecting the uptake of [(18)F]FAPI-42 were evaluated. In addition, the diagnostic performance and uptake of [(18)F]FAPI-42 and 2-[(18)F]FDG were compared, and the correlation between lesion diameter and quantitative parameters was investigated. RESULTS: A total of 161 lesions were detected in 27 (64%) patients on [(18)F]FAPI-42 PET/CT. FAPI-positive local recurrence showed the highest uptake intensity, followed by lymphatic, other site-associated (bone and pleura), and pulmonary lesions (mean SUV(max), 4.7 versus 3.7 versus 3.0 versus 2.2, respectively; P < 0.0001). The levels of TSH, Tg, and Tg-Ab did not affect the uptake value of lesions (median SUV(max): 2.4 versus 3.2, P = 0.56; 2.9 versus 2.4, P = 0.0935; 2.8 versus 2.6, P = 0.0525, respectively). A total of 90 positive lesions were detected in 7 patients using both modalities. All positive lesions showed statistically higher uptake of 2-[(18)F]FDG than that of [(18)F]FAPI-42 (SUV(max), 2.6 versus 2.1; P = 0.026). However, the SUV(max) of [(18)F]FAPI-42 was higher than that of 2-[(18)F]FDG in local recurrences and lymphatic lesions (SUV(max), 4.2 versus 2.9 and 3.9 versus 3.4, respectively; P > 0.05). CONCLUSION: [(18)F]FAPI-42 can be used for detecting lesions and reflecting FAP expression during local recurrence and metastasis in patients with DTC with biochemical elevations in Tg or anti-Tg antibodies. The diagnostic performance of [(18)F]FAPI-42 PET/CT is comparable with that of 2-[(18)F]FDG PET/CT in such patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-06067-2.
format Online
Article
Text
id pubmed-9931817
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-99318172023-02-17 [(18)F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[(18)F]FDG PET/CT Mu, Xingyu Huang, Xiaoxue Jiang, Zewen Li, Meng Jia, Lulu Lv, Zhongyuan Fu, Wei Mao, Jingsong Eur J Nucl Med Mol Imaging Original Article PURPOSE: This study aimed to assess the diagnostic performance of [(18)F]FAPI-42 PET/CT and compare it with that of 2-[(18)F]FDG PET/CT in patients with differentiated thyroid cancer (DTC) with biochemical elevations in Tg or anti-Tg antibodies. METHODS: A total of 42 patients with DTC with biochemical elevations in Tg or anti-Tg antibodies underwent [(18)F]FAPI-42 PET/CT as part of this study; of which, 11 additionally underwent 2-[(18)F]FDG PET/CT within 7 days. Images were semi-quantitatively and visually interpreted, and the quantity, location, and uptake values of lesions were noted. The diagnostic capacity of [(18)F]FAPI-42 PET/CT and biomarkers affecting the uptake of [(18)F]FAPI-42 were evaluated. In addition, the diagnostic performance and uptake of [(18)F]FAPI-42 and 2-[(18)F]FDG were compared, and the correlation between lesion diameter and quantitative parameters was investigated. RESULTS: A total of 161 lesions were detected in 27 (64%) patients on [(18)F]FAPI-42 PET/CT. FAPI-positive local recurrence showed the highest uptake intensity, followed by lymphatic, other site-associated (bone and pleura), and pulmonary lesions (mean SUV(max), 4.7 versus 3.7 versus 3.0 versus 2.2, respectively; P < 0.0001). The levels of TSH, Tg, and Tg-Ab did not affect the uptake value of lesions (median SUV(max): 2.4 versus 3.2, P = 0.56; 2.9 versus 2.4, P = 0.0935; 2.8 versus 2.6, P = 0.0525, respectively). A total of 90 positive lesions were detected in 7 patients using both modalities. All positive lesions showed statistically higher uptake of 2-[(18)F]FDG than that of [(18)F]FAPI-42 (SUV(max), 2.6 versus 2.1; P = 0.026). However, the SUV(max) of [(18)F]FAPI-42 was higher than that of 2-[(18)F]FDG in local recurrences and lymphatic lesions (SUV(max), 4.2 versus 2.9 and 3.9 versus 3.4, respectively; P > 0.05). CONCLUSION: [(18)F]FAPI-42 can be used for detecting lesions and reflecting FAP expression during local recurrence and metastasis in patients with DTC with biochemical elevations in Tg or anti-Tg antibodies. The diagnostic performance of [(18)F]FAPI-42 PET/CT is comparable with that of 2-[(18)F]FDG PET/CT in such patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-06067-2. Springer Berlin Heidelberg 2022-12-10 2023 /pmc/articles/PMC9931817/ /pubmed/36495325 http://dx.doi.org/10.1007/s00259-022-06067-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Mu, Xingyu
Huang, Xiaoxue
Jiang, Zewen
Li, Meng
Jia, Lulu
Lv, Zhongyuan
Fu, Wei
Mao, Jingsong
[(18)F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[(18)F]FDG PET/CT
title [(18)F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[(18)F]FDG PET/CT
title_full [(18)F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[(18)F]FDG PET/CT
title_fullStr [(18)F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[(18)F]FDG PET/CT
title_full_unstemmed [(18)F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[(18)F]FDG PET/CT
title_short [(18)F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[(18)F]FDG PET/CT
title_sort [(18)f]fapi-42 pet/ct in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[(18)f]fdg pet/ct
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931817/
https://www.ncbi.nlm.nih.gov/pubmed/36495325
http://dx.doi.org/10.1007/s00259-022-06067-2
work_keys_str_mv AT muxingyu 18ffapi42petctindifferentiatedthyroidcancerdiagnosticperformanceuptakevaluesandcomparisonwith218ffdgpetct
AT huangxiaoxue 18ffapi42petctindifferentiatedthyroidcancerdiagnosticperformanceuptakevaluesandcomparisonwith218ffdgpetct
AT jiangzewen 18ffapi42petctindifferentiatedthyroidcancerdiagnosticperformanceuptakevaluesandcomparisonwith218ffdgpetct
AT limeng 18ffapi42petctindifferentiatedthyroidcancerdiagnosticperformanceuptakevaluesandcomparisonwith218ffdgpetct
AT jialulu 18ffapi42petctindifferentiatedthyroidcancerdiagnosticperformanceuptakevaluesandcomparisonwith218ffdgpetct
AT lvzhongyuan 18ffapi42petctindifferentiatedthyroidcancerdiagnosticperformanceuptakevaluesandcomparisonwith218ffdgpetct
AT fuwei 18ffapi42petctindifferentiatedthyroidcancerdiagnosticperformanceuptakevaluesandcomparisonwith218ffdgpetct
AT maojingsong 18ffapi42petctindifferentiatedthyroidcancerdiagnosticperformanceuptakevaluesandcomparisonwith218ffdgpetct